Call Now

Rhesus HER2 / ErbB2 Protein (Fc Tag)

ErbB2, p185erbB2

Catalog Number P90020-K02H
Organism Species Rhesus
Host Human Cells
Synonyms ErbB2, p185erbB2
Molecular Weight The recombinant Rhesus ErbB2/Fc chimera is a disulfide-linked homodimer. The reduced monomer consists of 870 amino acids and predicts a molecular mass of 96.3 kDa. As a result of glycosylation, rhesus ErbB2/Fc monomer migrates as an approximately 130 kDa band in SDS-PAGE under reducing conditions.
predicted N Gln 24
SDS-PAGE
Purity > 90 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the Rhesus ErbB2 (XP_001090430.1) extracellular domain (Met 1-Thr 652) was fused with the Fc region of human IgG1 at the C-terminus.
Bio-activity Measured by its binding ability in a functional ELISA . Immobilized rhesus Erbb2-Fc at 2.5 μg/ml (100 μl/well) can bind Herceptin with a linear ranger of 6.4-160 ng/ml.
Research Area Cardiovascular |Angiogenesis |Growth Factor & Receptor |Receptor Tyrosine Kinase (RTK)
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
Reference
  • Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.